

Resource Summary Report

Generated by [NIF](#) on Jul 30, 2026

pT3-myr-AKT-HA

RRID:Addgene_31789

Type: Plasmid

Proper Citation

RRID:Addgene_31789

Plasmid Information

URL: <http://www.addgene.org/31789>

Proper Citation: RRID:Addgene_31789

Insert Name: Akt1

Organism: Mus musculus

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:21147110](#)

Vector Backbone Description: Backbone Size:7000; Vector Backbone:pT3-EF1a; Vector Types:Mammalian Expression; Bacterial Resistance:Ampicillin

Comments: This plasmid is in the pT3-EF1a vector which contains loxP sites flanking the inverted repeats of SB (sleeping beauty) sequence. Therefore this plasmid cannot not used with Cre for in vivo studies.

Plasmid Name: pT3-myr-AKT-HA

Record Creation Time: 20220422T222138+0000

Record Last Update: 20260725T074545+0000

Ratings and Alerts

No rating or validation information has been found for pT3-myr-AKT-HA.

No alerts have been found for pT3-myr-AKT-HA.

Data and Source Information

Usage and Citation Metrics

We found 42 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Hsieh TH, et al. (2025) Hinokiflavone is a novel CK2 inhibitor promoting apoptosis and synergizing with chemotherapeutic agents in cisplatin resistant bladder cancer cells. Scientific reports, 15(1), 20922.

Yuan S, et al. (2025) VDAC2 loss elicits tumour destruction and inflammation for cancer therapy. Nature, 640(8060), 1062.

Liu ZY, et al. (2025) Efflux of N1-acetylspermidine from hepatoma fosters macrophage-mediated immune suppression to dampen immunotherapeutic efficacy. Immunity, 58(6), 1572.

Tian W, et al. (2025) GCDH Acetylation Orchestrates DNA Damage Response and Autophagy via Mitochondrial ROS to Suppress Hepatocellular Carcinoma Progression. Research (Washington, D.C.), 8, 0862.

Shi G, et al. (2025) GFRAL-Fc disarms GDF15 to reprogram tumor immunity and amplify PD-1 efficacy in hepatocellular carcinoma. Cell communication and signaling : CCS, 23(1), 440.

Wang S, et al. (2025) The Role of the Hexosamine-Sialic Acid Metabolic Pathway Mediated by GFPT1/NANS in c-Myc-Driven Hepatocellular Carcinoma. Cellular and molecular gastroenterology and hepatology, 19(9), 101523.

Chen S, et al. (2025) Tumor-initiating cells escape tumor immunity via CCL8 from tumor-associated macrophages in mice. The Journal of clinical investigation, 135(5).

Wang F, et al. (2025) Suppression of Hepatocellular Carcinoma by Deletion of SIRT2 in Hepatocytes via Elevated C/EBP β /GADD45 β . Cellular and molecular gastroenterology and hepatology, 19(7), 101494.

Ren R, et al. (2024) Hu-lu-su-pian ameliorates hepatic steatosis by regulating CIDEA expression in AKT-driven MASLD mice. Frontiers in pharmacology, 15, 1503247.

Xu K, et al. (2024) Lymphotoxin beta-activated LTBR/NIK/RELB axis drives proliferation in cholangiocarcinoma. Liver international : official journal of the International Association for the Study of the Liver, 44(11), 2950.

Procel N, et al. (2024) In Vivo Tracking and 3D Mapping of Cell Death in Regeneration and Cancer Using Trypan Blue. Cells, 13(16).

Sun BY, et al. (2024) Mobilization and activation of tumor-infiltrating dendritic cells inhibits lymph node metastasis in intrahepatic cholangiocarcinoma. Cell death discovery, 10(1), 304.

Jessen M, et al. (2024) Inhibition of the YAP-MMB interaction and targeting NEK2 as potential therapeutic strategies for YAP-driven cancers. *Oncogene*, 43(8), 578.

Huang CX, et al. (2024) Pericancerous cross-presentation to cytotoxic T lymphocytes impairs immunotherapeutic efficacy in hepatocellular carcinoma. *Cancer cell*, 42(12), 2082.

Zhao W, et al. (2024) SLC13A3 is a major effector downstream of activated β -catenin in liver cancer pathogenesis. *Nature communications*, 15(1), 7522.

Chiu V, et al. (2024) Oncogenic plasmid DNA and liver injury agent dictates liver cancer development in a mouse model. *Clinical science (London, England : 1979)*, 138(19), 1227.

Chu Z, et al. (2023) A DNA/RNA heteroduplex oligonucleotide coupling asparagine depletion restricts FGFR2 fusion-driven intrahepatic cholangiocarcinoma. *Molecular therapy. Nucleic acids*, 34, 102047.

Jarman EJ, et al. (2023) DKK1 drives immune suppressive phenotypes in intrahepatic cholangiocarcinoma and can be targeted with anti-DKK1 therapeutic DKN-01. *Liver international : official journal of the International Association for the Study of the Liver*, 43(1), 208.

Chebotarev AS, et al. (2023) Multimodal label-free imaging of murine hepatocellular carcinoma with a subcellular resolution. *Journal of biophotonics*, 16(12), e202300228.

Allard B, et al. (2023) Adenosine A2A receptor is a tumor suppressor of NASH-associated hepatocellular carcinoma. *Cell reports. Medicine*, 4(9), 101188.